SHENYANG XINGQI PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of ophthalmic drugs. The Companyâs main products are ophthalmic prescription drugs, including corneal repairing drugs, anti-bacteria drugs, artificial tears, anti-inflammation drugs, anti-allergic drugs, as well as anti-hyperemia & fatigue relief drugs and others. The Company mainly distributes its products within domestic market.

Employees

1,995

Sector

Pharmaceuticals

Calendar

2025-04-17 - Q4 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
24-12-06	84.86 ¥	+1.07%	3,981,641
24-12-05	83.96 ¥	+0.67%	3,417,187
24-12-04	83.40 ¥	-3.43%	4,926,309
24-12-03	86.36 ¥	+0.58%	5,535,700
24-12-02	85.86 ¥	+3.52%	6,611,619

End-of-day quote Shenzhen S.E., December 05, 2024

More quotes

Income Statement and Estimates

income-statement-evolution-chart SHENYANG-XINGQI-PHARMACEU

More financial data

Annual profits - Rate of surprise

quality-estimates-chart SHENYANG-XINGQI-PHARMACEU

Company calendar

End-of-day quote Shenzhen S.E. Other stock markets 2024-12-06			5-day change	1st Jan Change
84.86 ^CNY	+1.07%		+2.31%	-34.84%

Oct. 28	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	CI
Sep. 23	Shenyang Xingqi Pharmaceutical Co.,Ltd.(XSEC:300573) added to FTSE All-World Index	CI

Capitalization	14.87B 2.05B 1.94B 1.79B 1.6B 2.89B 173B 3.2B 22.33B 8.25B 71.18B 7.68B 7.51B 307B	P/E ratio 2022	51.9x	P/E ratio 2023	94.5x
Enterprise value	14.47B 1.99B 1.88B 1.75B 1.56B 2.81B 169B 3.12B 21.73B 8.03B 69.26B 7.48B 7.31B 298B	EV / Sales 2022	8.46x	EV / Sales 2023	15.2x
Free-Float	68.04%	Yield 2022	1.2%	Yield 2023	2.03%

Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	Oct. 28	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd.(XSEC:300573) added to FTSE All-World Index	Sep. 22	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	Aug. 28	CI
Xingqi Pharmaceutical Gets Nod to Trial Eye Drops; Shares Up 4%	Jul. 25	MT
Xingqi Pharmaceutical Gets Nod to Register Bromfenac Sodium Eye Drops; Shares Down 3%	Jul. 24	MT
Space Peptides announced that it has received funding from Humanwell Healthcare Co.,Ltd., Shenyang Xingqi Pharmaceutical Co.,Ltd., Xiamen Furuier Pharmaceutical Co., Ltd., Purple Knight Capital and other investors	May. 21	CI
Shenyang Xingqi Pharmaceutical's Q1 Profit Jumps 80%	Apr. 26	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 18	CI
Xingqi Pharma Gets Nod to Market Atropine Sulfate Eye Drop; Shares Up 3%	Mar. 13	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Board Elections	Jan. 08	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd.(SZSE:300573) added to Shenzhen Stock Exchange Component Index	Dec. 12	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd.(SZSE:300573) added to Shenzhen Stock Exchange Component A Share Index	Dec. 12	CI

1 day	+1.07%
1 week	+2.31%
Current month	+2.31%
1 month	-8.58%
3 months	+7.44%
6 months	-54.55%
Current year	-34.84%

Shenyang Xingqi Pharmaceutical Co.,Ltd. Stock

Equities

300573

CNE100002DV1

Pharmaceuticals

Valuation: Shenyang Xingqi Pharmaceutical Co.,Ltd.

Chart: Shenyang Xingqi Pharmaceutical Co.,Ltd.

Latest news: Shenyang Xingqi Pharmaceutical Co.,Ltd.

Press Releases: Shenyang Xingqi Pharmaceutical Co.,Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Shenyang Xingqi Pharmaceutical Co.,Ltd.

ETFs: Shenyang Xingqi Pharmaceutical Co.,Ltd.

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

Director	Title	Age	Since
E Gao CEO	Chief Executive Officer	50	2022-07-17
Ya Nan Cheng DFI	Director of Finance/CFO	50	2011-11-11
Chun Hua Li ADM	Chief Administrative Officer	47	2022-02-15

Manager	Title	Age	Since
Xiao Yan Kong BRD	Director/Board Member	51	2024-01-04
Ji Dong Liu CHM	Chairman	67	2000-07-04
E Gao BRD	Director/Board Member	50	2011-11-11

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+1.07%	+2.31%	-31.27%	+31.52%	2.05B
MERCK KGAA	+0.05%	-1.31%	-1.58%	-36.82%	64.21B
KYOWA KIRIN CO. LTD.	+2.03%	+1.19%	+2.24%	-22.83%	8.34B
HALOZYME THERAPEUTICS, INC.	+0.71%	+0.41%	+21.15%	+45.61%	6.16B
YUHAN CORPORATION	-1.71%	-0.43%	+83.35%	+113.50%	6.05B
SK BIOPHARMACEUTICALS CO., LTD.	-2.21%	-1.55%	+12.86%	+1.29%	5.61B
BETTA PHARMACEUTICALS CO., LTD.	+3.83%	+3.92%	-0.33%	-28.96%	3.31B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+1.82%	+0.82%	+22.19%	+28.72%	2.27B
SUPERNUS PHARMACEUTICALS, INC.	+0.49%	+1.64%	+38.13%	+19.90%	2.05B
VELOXIS PHARMACEUTICALS A/S	-.--%	-.--%	-	-	1.64B
Average	+0.60%	-0.29%	+16.30%	+16.88%	10.17B
Weighted average by Cap.	+0.18%	-1.02%	+6.87%	-15.05%

	2022	2023
Net sales	1.25B 172M 163M 151M 135M 243M 14.56B 269M 1.88B 694M 5.98B 646M 631M 25.77B	1.47B 202M 191M 177M 158M 285M 17.1B 316M 2.2B 815M 7.02B 758M 741M 30.26B
Net income	212M 29.12M 27.55M 25.54M 22.84M 41.17M 2.47B 45.57M 318M 117M 1.01B 109M 107M 4.37B	240M 33.02M 31.24M 28.96M 25.9M 46.68M 2.8B 51.68M 360M 133M 1.15B 124M 121M 4.95B
Net Debt	-502M -69M -65.3M -60.53M -54.13M -97.56M -5.84B -108M -753M -278M -2.4B -259M -253M -10.34B	-401M -55.2M -52.23M -48.42M -43.3M -78.04M -4.67B -86.39M -602M -223M -1.92B -207M -203M -8.28B